LXRX

LEXICON PHARMACEUTICALS, INC.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

BULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 70% | 5/7/2026 | capital raiseNEUTRAL | 50% | 5/7/2026 | debt restructureBEARISH | 40% | 5/7/2026 | margin compressionBULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 70% | 5/7/2026 | capital raiseNEUTRAL | 50% | 5/7/2026 | debt restructureBEARISH | 40% | 5/7/2026 | margin compressionBULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 70% | 5/7/2026 | capital raiseNEUTRAL | 50% | 5/7/2026 | debt restructureBEARISH | 40% | 5/7/2026 | margin compressionBULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 70% | 5/7/2026 | capital raiseNEUTRAL | 50% | 5/7/2026 | debt restructureBEARISH | 40% | 5/7/2026 | margin compressionBULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 70% | 5/7/2026 | capital raiseNEUTRAL | 50% | 5/7/2026 | debt restructureBEARISH | 40% | 5/7/2026 | margin compressionBULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 70% | 5/7/2026 | capital raiseNEUTRAL | 50% | 5/7/2026 | debt restructureBEARISH | 40% | 5/7/2026 | margin compressionBULLISH | 90% | 5/7/2026 | earnings beatBULLISH | 70% | 5/7/2026 | capital raiseNEUTRAL | 50% | 5/7/2026 | debt restructureBEARISH | 40% | 5/7/2026 | margin compressionMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bullishMay 7

Net loss reduced significantly to $1.0M from $25.3M YoY.

earnings beat
90%
bullishMay 7

Raised $96.5M through common and preferred stock issuance.

capital raise
70%
neutralMay 7

Repaid Oxford Finance and entered into a $100M facility with Hercules Capital.

debt restructure
50%
bearishMay 7

Organic product revenue remains critically low relative to operating expenses.

margin compression
40%
bullishMay 7

Net loss reduced significantly to $1.0M from $25.3M YoY.

earnings beat
90%
bullishMay 7

Raised $96.5M through common and preferred stock issuance.

capital raise
70%
neutralMay 7

Repaid Oxford Finance and entered into a $100M facility with Hercules Capital.

debt restructure
50%
bearishMay 7

Organic product revenue remains critically low relative to operating expenses.

margin compression
40%
bullishMay 7

Net loss reduced significantly to $1.0M from $25.3M YoY.

earnings beat
90%
bullishMay 7

Raised $96.5M through common and preferred stock issuance.

capital raise
70%
neutralMay 7

Repaid Oxford Finance and entered into a $100M facility with Hercules Capital.

debt restructure
50%
bearishMay 7

Organic product revenue remains critically low relative to operating expenses.

margin compression
40%
bullishMay 7

Net loss reduced significantly to $1.0M from $25.3M YoY.

earnings beat
90%
bullishMay 7

Raised $96.5M through common and preferred stock issuance.

capital raise
70%
neutralMay 7

Repaid Oxford Finance and entered into a $100M facility with Hercules Capital.

debt restructure
50%
bearishMay 7

Organic product revenue remains critically low relative to operating expenses.

margin compression
40%
bullishMay 7

Net loss reduced significantly to $1.0M from $25.3M YoY.

earnings beat
90%
bullishMay 7

Raised $96.5M through common and preferred stock issuance.

capital raise
70%
neutralMay 7

Repaid Oxford Finance and entered into a $100M facility with Hercules Capital.

debt restructure
50%
bearishMay 7

Organic product revenue remains critically low relative to operating expenses.

margin compression
40%
bullishMay 7

Net loss reduced significantly to $1.0M from $25.3M YoY.

earnings beat
90%
bullishMay 7

Raised $96.5M through common and preferred stock issuance.

capital raise
70%
neutralMay 7

Repaid Oxford Finance and entered into a $100M facility with Hercules Capital.

debt restructure
50%
bearishMay 7

Organic product revenue remains critically low relative to operating expenses.

margin compression
40%
bullishMay 7

Net loss reduced significantly to $1.0M from $25.3M YoY.

earnings beat
90%
bullishMay 7

Raised $96.5M through common and preferred stock issuance.

capital raise
70%
neutralMay 7

Repaid Oxford Finance and entered into a $100M facility with Hercules Capital.

debt restructure
50%
bearishMay 7

Organic product revenue remains critically low relative to operating expenses.

margin compression
40%